UBS maintains a 'Neutral' on PharMerica (NYSE: PMC), lowers price target from $19 to $16.

UBS sees nice upside ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE